Evidence map›Paper›PMID 39748841›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)

Relationship between physical activity and biomarkers of pathology and neuroinflammation in preclinical autosomal-dominant Alzheimer's disease.

Edmarie Guzmán-Vélez, Angelys Rivera-Hernández, Sofia Fabrega, Gabriel Oliveira, Jairo E Martínez, Ana Baena, Glen Picard, Francisco Lopera, Steven E Arnold, J Andrew Taylor and 1 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Edmarie Guzmán-VélezDepartment of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
Angelys Rivera-HernándezUniversity of Puerto Rico-Río Piedras San Juan Puerto Rico USA.
Sofia FabregaDepartment of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
Gabriel OliveiraDepartment of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
Jairo E MartínezDepartment of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
Ana BaenaGrupo de Neurociencias de Antioquia, Facultad de Medicina Universidad de Antioquia Medellín Colombia.
Glen PicardCardiovascular Research Laboratory Spaulding Rehabilitation Hospital Cambridge Massachusetts USA.
Francisco LoperaGrupo de Neurociencias de Antioquia, Facultad de Medicina Universidad de Antioquia Medellín Colombia.
Steven E ArnoldDepartment of Neurology, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.
J Andrew TaylorCardiovascular Research Laboratory Spaulding Rehabilitation Hospital Cambridge Massachusetts USA.
Yakeel T QuirozDepartment of Psychiatry, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Neuroscience Research Opportunities to Increase Diversity (NeuroID)R25NS080687 · NINDS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI GARCIA-ARRARAS, JOSE E, MALDONADO-VLAAR, CARMEN SARA · 2012 to 2024
$5.3M
Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant DementiasRM1NS132996 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, ARBOLEDA-VELASQUEZ, JOSEPH · 2023 to 2023
$3.8M
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Memory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3M
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's diseaseRF1AG077627 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI AGUILLON, DAVID FERNANDO, CUELLO, A CLAUDIO · 2022 to 2022
$2.0M
Aerobic fitness as a modifier of neurodegeneration and cognitive decline in preclinical Alzheimer's diseaseK23AG061276 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GUZMÁN-VÉLEZ, EDMARIE · 2019 to 2023
$881k
NIA NIH HHS K23 AG061276NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG054671NIA NIH HHS RF1 AG077627NIH HHS DP5 OD019833NINDS NIH HHS R25 NS080687NINDS NIH HHS RM1 NS132996
6 · The paper itself

Abstract

Objective: Physical activity (PA) has been linked to reduced Alzheimer's disease (AD) risk. However, less is known about its effects in the AD preclinical stage. We aimed to investigate whether greater PA was associated with lower plasma biomarkers of AD pathology, neural injury, reactive astrocytes, and better cognition in individuals with autosomal-dominant AD due to the presenilin-1 E280A mutation who are virtually guaranteed to develop dementia. Methods: Twenty-eight cognitively unimpaired mutation carriers (ages x̄ = 29.28) wore a FitBit Charge-4 for 14 days. We calculated their average steps to measure locomotion, and Training Impulse (TRIMP) to quantify the intensity and duration of PAs using heart rate. Plasma amyloid beta 42/40 ratio, phosphorylated tau 181, neurofilament light chain, and glial fibrillary acidic protein (GFAP) were measured. Cognition was assessed with the Consortium to Establish a Registry for Alzheimer's Disease word list learning and delayed recall, Trail Making Test Part A, and Wechsler Adult Intelligence Scale-version IV Digit Span Backward. We conducted multiple linear regressions controlling for age, sex, body mass index, and education. Results: There were no associations among steps or TRIMP with plasma biomarkers or cognition. Greater TRIMP was related to higher GFAP levels. Conclusions: PA was not associated with cognition or plasma biomarkers. However, greater intensity and duration of PAs were related to higher GFAP. Participants engaged very little in moderate to vigorous PA. Therefore, light PA may not exert a significant protective effect in preclinical AD. Future work with larger samples and longitudinal data is needed to elucidate further the potential impact of PA on AD progression in the preclinical stages. Highlights: Locomotion (average steps) was not associated with plasma biomarkers or cognition.Greater training load (training impulse) was related to higher glial fibrillary acidic protein levels in mutation carriers.Light physical activity may not suffice to exert a protective effect on Alzheimer's disease.

Indexed as

early onset Alzheimer's diseaseexerciseglial fibrillary acidic proteinneurofilament light chainphosphorylated tau 181presenilin‐1 E280A

Identifiers

PMID39748841
PMCPMC11694529

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.